Molecular Residual Disease After Definitive Chemoradiotherapy in Locally Advanced Head and Neck Cancer: Clinical Value and Optimal Timing for ctDNA Assessment.

BACKGROUND: Accurate post-treatment assessment after definitive chemoradiotherapy (CRT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains challenging due to limitations of standard imaging. We evaluated the diagnostic performance, prognostic value and optimal timing of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection. METHODS: Seventy-four patients with LA-HNSCC treated with definitive CRT were prospectively enrolled. Plasma samples were collected before treatment, at 8 and 12 weeks after CRT, and during follow-up. ctDNA was analysed using a plasma-only methylation-based assay. Diagnostic performance for recurrence detection and associations with progression-free survival (PFS) and overall survival (OS) were evaluated and compared with 12-week PET/CT findings. RESULTS: Baseline ctDNA was detectable in 85.1% of patients. Among post-treatment timepoints, week-12 ctDNA showed the highest diagnostic accuracy for recurrence detection, with 69% sensitivity, 100% specificity, 100% positive predictive value, and 76% negative predictive value. Detectable week-12 ctDNA was associated with shorter PFS (HR, 6.44; 95% CI, 2.73-16.74; p<0.001) and OS (HR, 7.31; 95% CI, 2.80-22.31; p<0.001 ). Longitudinal ctDNA surveillance identified additional recurrences among patients with initially undetectable week-12 ctDNA. Exploratory analyses integrating PET/CT and ctDNA identified prognostically distinct PFS groups (log-rank P=0.033), with the greatest additional prognostic stratification observed among PET partial-responders. CONCLUSIONS: Plasma-only methylation-based ctDNA provided high-specificity prognostic information after definitive CRT in LA-HNSCC, particularly at week 12 and in PET partial-responders. ctDNA may complement PET/CT for post-treatment risk stratification, but should not be used as a stand-alone test to exclude recurrence.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-17
DOI
https://doi.org/10.1158/1078-0432.ccr-26-1545
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Molecular Residual Disease After Definitive Chemoradiotherapy in Locally Advanced Head and Neck Cancer: Clinical Value and Optimal Timing for ctDNA Assessment.

Clara Alfaro‐Cervelló, Blanca García-Micó, Jorge Martín-Arana, María Maroñas et al.
5 links
Clinical Cancer Research
Head and Neck Cancer Studies
article

Molecular Residual Disease After Definitive Chemoradiotherapy in Locally Advanced Head and Neck Cancer: Clinical Value and Optimal Timing for ctDNA Assessment.

Clara Alfaro‐Cervelló, Blanca García-Micó, Jorge Martín-Arana, María Maroñas, Delfina Dualde, Franz Villarroel‐Espíndola, Gema Bruixola, Daniel G. Camblor, Noelia Tarazona, Francisco Gimeno-Valiente, Andrès M.R. Cervantes, Nuria Grimalt, Belén Martínez-Castedo, María Eugenia Iglesias, Vicente Escorihuela García, F. Martinez Martinez, B. Iglesias, Jim Hayes, Miguel García Bartolomé, Alonso García-Márquez
article en

Abstract

BACKGROUND: Accurate post-treatment assessment after definitive chemoradiotherapy (CRT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains challenging due to limitations of standard imaging. We evaluated the diagnostic performance, prognostic value and optimal timing of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection. METHODS: Seventy-four patients with LA-HNSCC treated with definitive CRT were prospectively enrolled. Plasma samples were collected before treatment, at 8 and 12 weeks after CRT, and during follow-up. ctDNA was analysed using a plasma-only methylation-based assay. Diagnostic performance for recurrence detection and associations with progression-free survival (PFS) and overall survival (OS) were evaluated and compared with 12-week PET/CT findings. RESULTS: Baseline ctDNA was detectable in 85.1% of patients. Among post-treatment timepoints, week-12 ctDNA showed the highest diagnostic accuracy for recurrence detection, with 69% sensitivity, 100% specificity, 100% positive predictive value, and 76% negative predictive value. Detectable week-12 ctDNA was associated with shorter PFS (HR, 6.44; 95% CI, 2.73-16.74; p<0.001) and OS (HR, 7.31; 95% CI, 2.80-22.31; p<0.001 ). Longitudinal ctDNA surveillance identified additional recurrences among patients with initially undetectable week-12 ctDNA. Exploratory analyses integrating PET/CT and ctDNA identified prognostically distinct PFS groups (log-rank P=0.033), with the greatest additional prognostic stratification observed among PET partial-responders. CONCLUSIONS: Plasma-only methylation-based ctDNA provided high-specificity prognostic information after definitive CRT in LA-HNSCC, particularly at week 12 and in PET partial-responders. ctDNA may complement PET/CT for post-treatment risk stratification, but should not be used as a stand-alone test to exclude recurrence.

Clinical Cancer Research
Massachusetts General Hospital (US), Hospital Clínico Universitario de Valencia (ES), Consorcio Hospitalario Provincial de Castellón (ES), Guardant (United States) (US), UCL Biomedical Research Centre (GB), INCLIVA Health Research Institute (ES), University College London (GB)
Fundación Mutua Madrileña, INCLIVA Instituto de Investigación Sanitaria, Instituto de Salud Carlos III
Good health and well-being
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon